OBJECTIVES:  This study aimed to assess price differences of oncology and non-oncology orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK by comparing the annual treatment cost per patient of similarly available drugs. METHODS:  Orphan drugs granted market authorisation up to June 13, 2016 were extracted from the European Medicines Agency website and divided into oncology and non-oncology. The annual treatment costs per drug were calculated based on the summary of product characteristics (SmPC) using ex-factory prices from IHS POLI and country price databases. The treatment cost in the each country (comparator country) was compared to the UK (reference country) and ratios were analysed for both oncology and non-oncology drugs. The absolute value of the median annual treatment costs of non-oncology and oncology orphan drugs within each country was also analysed RESULTS: